Jefferies Financial Group Inc. Buys Shares of 87,800 Xeris Biopharma Holdings, Inc. $XERS

Jefferies Financial Group Inc. acquired a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 87,800 shares of the company’s stock, valued at approximately $689,000. Jefferies Financial Group Inc. owned 0.05% of Xeris Biopharma at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. AlphaQuest LLC bought a new stake in shares of Xeris Biopharma during the 3rd quarter valued at $35,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Xeris Biopharma by 29.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after acquiring an additional 1,820 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in Xeris Biopharma by 179.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after buying an additional 5,000 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Xeris Biopharma by 913.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 17,395 shares of the company’s stock worth $81,000 after buying an additional 15,678 shares in the last quarter. Finally, Modern Wealth Management LLC purchased a new stake in Xeris Biopharma in the 2nd quarter worth $83,000. Institutional investors own 42.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on XERS shares. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a report on Monday, March 2nd. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $10.80.

Insider Transactions at Xeris Biopharma

In related news, insider Beth Hecht sold 16,667 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $6.25, for a total value of $104,168.75. Following the sale, the insider directly owned 1,226,507 shares of the company’s stock, valued at $7,665,668.75. This represents a 1.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director James Aloysius Brady sold 10,834 shares of the stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $5.54, for a total transaction of $60,020.36. Following the completion of the sale, the director directly owned 89,166 shares in the company, valued at $493,979.64. This trade represents a 10.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 60,835 shares of company stock valued at $367,860. 6.47% of the stock is owned by insiders.

Xeris Biopharma Stock Down 2.5%

Shares of NASDAQ:XERS opened at $6.16 on Friday. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. Xeris Biopharma Holdings, Inc. has a 12 month low of $4.30 and a 12 month high of $10.08. The company has a 50-day moving average price of $6.04 and a 200 day moving average price of $6.64. The company has a market cap of $1.06 billion, a price-to-earnings ratio of 102.67 and a beta of 0.85.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The firm had revenue of $83.13 million during the quarter, compared to the consensus estimate of $79.83 million. As a group, equities research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.